Guggenheim Starts Theravance Biopharma (TBPH) at Buy
Tweet Send to a Friend
Guggenheim initiates coverage on Theravance Biopharma (NASDAQ: TBPH) with a Buy rating and a price target of $30.00.Analyst Louise Chen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE